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Abstract 
Background: The human immunodeficiency virus type‑1 (HIV‑1) nucleocapsid protein (NC) is an essential and multi‑
functional protein involved in multiple stages of the viral life cycle such as reverse transcription, integration of proviral 
DNA, and especially genome RNA packaging. For this reason, it has been considered as an attractive target for the 
development of new anti‑HIV drugs. Although a number of inhibitors of NC have been reported thus far, the search 
for NC‑specific and functional inhibitor(s) with a good antiviral activity continues.
Results: In this study, we report the identification of A1752, a small molecule with inhibitory action against HIV‑1 NC, 
which shows a strong antiviral efficacy and an IC50 around 1 μM. A1752 binds directly to HIV‑1 NC, thereby inhibiting 
specific chaperone functions of NC including Psi RNA dimerization and complementary trans‑activation response ele‑
ment (cTAR) DNA destabilization, and it also disrupts the proper Gag processing. Further analysis of the mechanisms 
of action of A1752 also showed that it generates noninfectious viral particles with defects in uncoating and reverse 
transcription in the infected cells.
Conclusions: These results demonstrate that A1752 is a specific and functional inhibitor of NC with a novel mode of 
action and good antiviral efficacy. Thus, this agent provides a new type of anti‑HIV NC inhibitor candidate for further 
drug development.
Keywords: HIV‑1, NC inhibitor, Psi RNA dimerization, Noninfectious virus, Gag processing, Core uncoating
© 2015 kim et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The human immunodeficiency virus type-1 (HIV-1) 
nucleocapsid protein (NC) is derived from the Gag 
polyprotein precursor by the viral protease during viral 
assembly [1]. It is a small, basic, nucleic acid binding 
protein with two zinc fingers that are highly conserved 
among the retroviruses [2–4]. Many previous genetic 
studies have shown that mutations in the NC result 
in various phenotypes, which include defects in viral 
genomic RNA (gRNA) packaging [5–8]. There is also 
a loss of viral infectivity, abnormality of Gag processing 
and viral core stability as well as inhibition of viral DNA 
synthesis in infected cells [9–11]. All these observations 
are indicative of the undoubted importance of NC in viral 
replication. The NC plays many essential roles through-
out the life cycle of the HIV and is, therefore, considered 
a new promising and attractive target for the develop-
ment of new anti-HIV drugs [12, 13].
To date, a number of zinc ejector type of inhibi-
tors targeting the zinc fingers of NC, which are a criti-
cal motif for protein function, have been reported. For 
example, inhibitors like C-nitrosobenzamide (NOBA) 
[14], disulfide-substituted benzamide (DIBA) [15], 
1,2-dithiane-4,5-diol, 1,1-dioxide, cis (Dithiane) [16], 
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azodicarbonamide (ADA) [17], pyridinioalkanoyl thi-
olester (PATE) [18], thiolcarbamates (TICAs) [19], and 
S-acyl-2-mercaptobenzamide thioester (SAMT) [20] 
have been shown to target the zinc ion of the HIV-1 
NC and inhibit HIV-1 replication. Subsequently, DIBA, 
Dithiane, and SAMT have shown similar effects by 
inducing intermolecular cross-links between cysteins in 
the zinc fingers of NC in Gag protein. This action causes 
modification and aggregation of the NC and Gag pro-
tein, which results in disturbance of Gag processing [15, 
16, 20]. ADA was also reported to induce the modifica-
tion of NC in viruses and thereby prevent reverse tran-
scription of HIV-1 [17]. However, further development 
of these types of zinc ejector inhibitors has been mostly 
limited in part due to either a low or lack of target speci-
ficity and cellular toxicity [21, 22]. Recently, there are 
also other types of NC-zinc ejectors reported such as 
N,N’-bis(4-ethoxycarbonyl-1,2,3-thiadiazol-5-yl)ben-
zene-1,2-diamine (NV038) and 2-methyl-3-phenyl-2H- 
[1, 2, 4] thiadiazol-5-ylideneamine (WDO-217), which 
have not shown covalent bonds in NC [23, 24] unlike the 
aforementioned inhibitors.
The functional contributions of NC to HIV-1 repli-
cation are achieved mostly by its chaperone functions 
to various forms of viral nucleic acids through specific 
interactions [25–28]. For this reason, small molecule 
antagonists, which could inhibit the NC-mediated 
complementary trans-activation response element 
(cTAR) DNA destabilization or λ-DNA stretching 
in vitro, have also been explored [29, 30]. However, the 
cellular antiviral efficacy of these molecules has shown 
either quite low [30, 31] or not yet determined [29].
Lately, a series of compounds have been reported 
to disrupt the binding between NC and synthetic 
viral nucleic acids without NC zinc ejection, and 
a few of them exhibited good binding affinity to NC 
but showed rather modest antiviral activities [32]. In 
spite of these efforts thus far, the search for new types 
of small molecule NC inhibitors, which could bind 
strongly and specifically to NC and inhibit its known 
functions, thereby effectively suppress viral replica-
tion, is still warranted.
Toward the goal, we previously developed a cell-based 
screening assay system to probe specific interactions 
between the NC and the viral packaging signal sequence 
RNA, Psi, element [33] and have screened various chemi-
cal libraries that inhibit the interaction. A number of pos-
sible inhibitors have been identified, and their antiviral 
activities have been examined. Here, we report on A1752, 
a novel small molecule NC inhibitor, which strongly 
binds the HIV-1 NC thereby inhibiting the chaperone 
properties of NC and leading to good antiviral activity 
against the HIV-1.
Results
Identification of A1752, a new HIV‑1 inhibitor
To assess the antiviral efficacy of a newly identified small 
molecule inhibitor designated as A1752 (Fig. 1a) against 
HIV-1, we used an HIV-1 NL4-3 isolate derivative har-
boring enhanced green fluorescent protein (NL4-3/
EGFP). This allows the viral replication and infection to 
be easily probed simply by the observation of the EGFP 
expression in the virus-infected cells [34]. The MT-4 
cells were infected with the virus at a 0.05 multiplicity 
of infection (MOI) and treated with various concentra-
tions of the A1752. The HIV-1 inhibitor Tenofovir was 
used as the control. After the cells had been incubated 
for 3 days in which cells were remained mostly viable, the 
viral production was measured using an enzyme-linked 
immunosorbent assay (ELISA). The half-maximal inhibi-
tory concentration (IC50) of A1752 was determined to be 
around 1.0–2.0 μM, which is similar to the antiviral effi-
cacy of Tenofovir (Fig. 1b).
Treatment with A1752 decreased dose-dependently the 
expression of EGFP in the virus-infected cells (Fig.  1c), 
which nicely supported further the antiviral efficacy 
of A1752 determined. The observed antiviral effect of 
A1752 was not mediated by any cellular toxicity since 
the 50  % cytotoxicity concentration (CC50) of A1752 
was determined to be much higher than 50 μM (Fig. 1d). 
Also, we found that A1752 had little effect on the activ-
ity of HIV-1 reverse transcriptase (RT) and integrase (IN) 
(Additional file  1: Figure S1 and Additional file  2: Fig-
ure S2), indicating that they are not inhibitory targets of 
A1752.
A1752 binds directly to HIV‑1 NC protein
To determine in fact the capacity of A1752 to bind spe-
cifically to the HIV-1 NC target, we used a surface plas-
mon resonance (SPR) assay. The titration sensorgram 
showed that the A1752 bound strongly to the NC dose-
dependently (Fig. 2a). The analysis of the binding kinetics 
result using a 1:1 Langmuir binding model provided by 
the manufacturer (GE Healthcare) revealed the dissocia-
tion constant value (KD) between A1752 and NC to be in 
the range of 20 nM (Additional file 3: Table S1). In addi-
tion, we performed an intrinsic tryptophan fluorescence 
quenching assay of NC to further examine its interaction 
with A1752. The result clearly demonstrated that A1752 
was able to bind dose-dependently to the HIV-1 NC 
(Fig. 2b).
A1752 inhibits NC‑mediated dimerization of Psi RNA 
and cTAR DNA destabilization
Having established the high affinity binding of A1752 to 
NC protein, we further examined the effects of A1752 
on the nucleic acid chaperone function of NC. Firstly, 
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we examined the effects of A1752 on the specific bind-
ing of NC to Psi RNA and resulting NC-mediated Psi 
RNA dimerization. As shown in Fig. 2c, A1752 but not 
the control compounds inhibited dose-dependently both 
the NC-induced stable dimerization of HIV-1 Psi RNA 
and the NC-Psi RNA complex formation. NC is also 
a known cofactor of HIV-1 RT and mediates its chap-
erone activities [35]. During the reverse transcription 
reaction, NC functions in an important role of prevent-
ing the self-annealing and -priming of cTAR DNA. This 
Fig. 1 Anti‑ HIV efficacy of a new small chemical inhibitor A1752. a The chemical structure of A1752, (Z)‑3‑(5‑((5‑(4‑chlorophenyl)furan‑2‑yl)
methylene)‑4‑oxo‑2‑thioxothiazolidin‑3‑yl)propanoic acid. b Determination of anti‑HIV activity of A1752. Inhibition of HIV‑1 production in MT‑4 
cells infected with a HIV‑1 NL4‑3/EGFP in the presence of A1752 or a control inhibitor Tenofovir was determined using HIV‑1 p24 ELISA. Data are the 
mean ± SD of triplicate experiments for each concentration. c Examination of EGFP expression as a surrogate marker for HIV‑1 replication in the 
infected MT‑4 cells treated with the inhibitors in (b) was examined on day 3 post infection. d Cellular toxicity of the A1752 was measured using a 
Cell‑Titer Glo assay and the percentage cell survival in the presence of each indicated compound compared to that of non‑treated cells. Data are 
the mean ± SD of three separate experiments
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Fig. 2 Specific interaction of A1752 with HIV‑1 NC and functional inhibition of NC‑mediated chaperone activities. a The determination of binding 
affinity of A1752 to NC using SPR assay. b Tryptophan fluorescence quenching assay. Shown is intrinsic tryptophan quenching of NC by A1752. 
NC (5 μM) was used and excitation wavelength was 280 nm and emission was scanned from 310 to 450 nm as shown. c Effect of A1752 on NC‑
mediated HIV‑1 Psi RNA dimerization (Top) and NC‑Psi complex formation as determined by gel‑shift assay (Bottom). Monomeric and dimeric Psi 
RNA and Psi RNA‑NC complex were probed with a SYBR green staining method for RNA and a SYPRO Ruby staining for protein, respectively. Control 
bands for monomeric and heat‑induced dimeric Psi RNA are also indicated in lane 1 and 2, respectively. NC was incubated with A1752 at increasing 
molar ratio (1:1, 1:10, 1:25, and 1:50), DMSO and AZT (1:50) as described in “Methods”. d Inhibition of NC‑induced cTAR destabilization by A1752. NC 
(1 μM) were preincubated for 10 min with increasing A1752 concentrations or other inhibitors, DIBA and SAMT, as indicated and added to 0.1 μM 
of doubly‑labeled Rh6G‑5′‑cTAR‑3′‑DABCYL DNA for 1 h. Fluorescence change was monitored at excitation and emission wavelength of 520 and 
560 nm, respectively
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facilitates the synthesis of a proper DNA intermediate at 
the first-strand transfer step of the reverse transcription. 
Therefore, we examined the effects of A1752 on NC-
mediated cTAR DNA destabilization. The cTAR DNA 
was double-labeled with 6-carboxyrhodamine (Rh6G) 
and 4-(4′-dimethylamino phenylazo) benzoic acid 
(DABCYL), which served as the fluorescence donor and 
quencher at its 5′- and 3′-ends, respectively, as reported 
previously [36]. The addition of NC promotes the open-
ing the cTAR stem structure by its chaperone activity. 
Thus, the fluorescence intensity of the Rh6G-5′-cTAR-
3′-DABCYL DNA was increased by treatment with NC 
alone as expected (Additional file  4: Figure S3). To test 
inhibitory effect of A1752, the NC was pretreated with 
A1752 as well as the previously reported NC zinc finger 
targeting inhibitors, DIBA or SAMT. The fluorescence 
intensities were decreased concentration-dependently 
by A1752, indicating that it inhibited the cTAR desta-
bilization activity of NC. Interestingly, both DIBA and 
SAMT showed a little effect on the NC-mediated cTAR 
destabilization under the same condition (Fig.  2d). A 
similar lack of inhibition was also observed in the NC-
mediated Psi RNA dimerization assay (data not shown). 
These results together suggest further that A1752 is a 
bona-fide functional inhibitor that acts by specifically 
binding to NC and suppressing the NC-associated chap-
erone functions.
Treatment with A1752 produces noninfectious HIV‑1
To understand molecular mechanisms of the antiviral 
activity of A1752, we examined the infectivity of viral 
particles generated after treatment with A1752 using a 
reinfection assay as described schematically in Fig.  3a. 
Firstly, the MT-4 cells were infected with the HIV-1 
NL4-3/EGFP virus and then treated with A1752 or the 
other control compounds. Similar to the results illus-
trated in Fig. 1b, viral production was again significantly 
inhibited by A1752 as all the other control inhibitors 
used (Fig.  3b). Next, we examined the infectivity of the 
resulting viruses produced. This was achieved by infect-
ing fresh MT-4 cells with the same amount of purified 
and quantified virus particles released from the infec-
tion in each case. There were no further chemical inhibi-
tors added or carry-over conditions as described in the 
“Methods”. As shown in Fig. 3c, all the viruses generated 
in the presence of the other inhibitors including azidothy-
midine (AZT), Tenofovir, DIBA, and SAMT showed an 
equal level of infection like the DMSO positive control. 
Surprisingly, however, infection of the viruses generated 
from the A1752-treated cells was attenuated sharply and 
A1752 dose-dependently (Fig. 3c), indicating the produc-
tion of non-infectious virus by the A1752.
Virions generated in the presence of A1752 are 
defective in synthesis of the viral early RT product in the 
virus‑infected cells
To further characterize the inhibition and loss of viral 
infectivity induced by the A1752, we examined the syn-
thesis of RT products in the virion-infected cells. We 
measured the minus strand strong-stop (-)ssDNA, an 
early viral RT product, using the quantitative real-time 
polymerase chain reaction (qPCR) method. Notably, the 
production of the (-)ssDNA was significantly decreased 
in cells infected with virion generated in the presence of 
A1752 (Fig.  3d). The synthesis of the (-)ssDNA product 
was suppressed up to 60  % at 1  μM and nearly 90  % at 
5 μM, even though the viral RNA template was detected 
at a similar level in the infected cells (Fig. 3e), This result 
indicated that RT reaction following the infection was 
non-productive and accounts in part for the appearance 
of the A1752-induced defective and non-infectious virus 
phenotype. It is noteworthy that this phenomenon was 
not caused by the inhibition of RT activity by A1752 as it 
was determined that the HIV-1 RT reverse transcriptase 
was not affected by A1752. In addition, we observed that 
at a higher concentration of around 20 μM of A1752, the 
HIV-1 gRNA packaging was inhibited to some extent 
(Additional file 5: Figure S4), suggesting that higher con-
centrations of this inhibitor might also affect gRNA pack-
aging mediated by NC during viral RNA assembly.
A1752 produce non‑infectious viruses in a proviral DNA 
and lentiviral vector transfection system
The non-infectious virus phenotype observed in the rein-
fection assay suggests that the antiviral activity of A1752 
most likely occurs in the late stage of the virus life cycle, 
which includes the viral packaging and assembly stage. 
To further confirm this, we first examined the infectivity 
of the virus generated using a transfection system of the 
HIV-1 proviral DNA, which reflects only the late stages 
of the HIV-1 life cycle following viral integration. The 
293FT cells were transfected with a pNL43/EGFP pro-
viral DNA followed by treatment with A1752, and then 
the transfected cells and viral supernatant were analyzed 
48  h after transfection. The results showed that A1752 
had no influenced on the viral gene expression since the 
same level of EGFP expression was observed in all the 
test cases (Fig. 4a). In addition, the viral translation and 
budding for virus production was also unaffected. This 
was verified by the p24 ELISA measurements show-
ing that A1752 had no inhibitory effect on the produc-
tion and release of virus particles (bottom of Fig. 4a). A 
similar result was also obtained with all the other control 
HIV-1 inhibitors including AZT, Tenofovir, DIBA, and 
SAMT.
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Fig. 3 Generation of noninfectious virus by A1752. a A schematic representation of a reinfection experiment to examine infectivity of virus 
produced. b Comparison of antiviral activity of A1752 with other anti‑HIV inhibitors. MT‑4 cells were infected with HIV‑1 NL4‑3/EGFP virus in the 
presence of the indicated inhibitors. Viral production was determined using HIV‑1 p24 ELISA. AZT, Tenofovir, DIBA, and SAMT were also used for 
comparison. c Determination of infectivity (Reinfection assay) of the viruses obtained in b. Fresh MT‑4 cells were infected with the same amount 
(2.5 ng in p24) of purified viral particles produced from the infection assay in (b) in the absence of any inhibitors. Then, the GFP expressing cells 
were quantified using FACS analysis 48 h after the infection. d The viral (‑)ssDNA, an early RT product, produced for 6 h after infection with viruses of 
each case from (b) was determined using qPCR. Data are the mean ± SEM of three separate experiments. e Determination of HIV‑1 gRNA in MT‑4 
cells infected with an equal amount (30 ng in p24) of the virus particles produced from (b). At 3 h after infection, total cellular RNA was analyzed 
using northern‑blot for detection of gRNA in the infected MT‑4 cells. Gag‑specific probe was for HIV‑1 gRNA and an actin probe was used as a load‑
ing control
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Next, to test the infectivity of the viruses released from 
the transfected cells in each case, fresh MT-4 cells were 
infected again with an equal amount of the viral parti-
cles produced. The infections were successfully observed 
in cases with all the other control compounds including 
AZT, Tenofovir, DIBA, SAMT, and DMSO. However, the 
viral infectivity was completely attenuated at an inhibi-
tion level of over 95 % with 1 μM of A1752, despite the 
normal level of virus production (Fig. 4a, b). This result 
suggests clearly that the viral particles produced in the 
Fig. 4 Effect of A1752 on infectivity of viruses generated by proviral DNA transfection and lentiviral system. The 293FT cells were transfected with a 
pNL4‑3EGFP HIV‑1‑proviral DNA in the presence of the indicated inhibitors. a Post‑transfection 48 h, EGFP expression within cells and viral produc‑
tion were analyzed, respectively. b An equal amount (2.5 ng in p24) of the virions produced in each case in (a) was taken to infect to MT‑4 cells as 
described in Fig. 3, and the infection was analyzed using both a fluorescence microscopic observation of EGFP expression and quantitative FACS 
analysis (% of GFP) 48 h after infection. c 293FT cells were transfected with a pLenti/EGFP transgene plasmid and packaging plasmids (pLP1, pLP2, 
and pLP/VSVG) in the presence of the inhibitors indicated (middle column) The same amounts (10 ng in p24) of lentiviral vectors produced under 
the conditions were subjected to infection to fresh MT‑4 cells and followed by determination of level of EGFP expression (the last column), and d 
HT1080 colony assay for the determination of the lentiviral vector infectivity. The colony forming units (CFU) were compensated with p24 ELISA 
values for the virus particles used in each case. Data are the mean ± SEM of three separate experiments
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presence of A1752 were non-infectious as seen in the 
MT-4 cell infection system.
To further confirm the generation of non-infectious 
viruses, we also examined the effect of A1752 on the 
viruses generated using a lentiviral vector system, which 
uses an heterologous viral entry glycoprotein VSV-G 
rather than that of HIV-1. This system permits only a sin-
gle round of infection and, for this reason, is an excellent 
system to evaluate the effects of A1752 on only the viral 
assembly and maturation step. The results also revealed 
no observable differences in the expression of the green 
fluorescence protein (GFP) following transfection with 
the lentiviral vector with or without the inhibitors tested, 
showing an equal transfection efficiency and production 
of lentiviruses (Fig.  4c). However, the infectivity of the 
lentiviruses generated in the presence of A1752 but not 
AZT or SAMT, was significantly decreased in both the 
GFP-positive infected cell count and a separate cell col-
ony assay used for lentivirus titer determination (Fig. 4c, 
d). These results clearly demonstrate further that treat-
ment with the NC inhibitor A1752 leads to the release 
of non-infectious defective viruses. This also confirms 
that that the inhibitory action of the A1752 occurs in the 
late phase of the virus life cycle such as viral packaging 
and maturation and thus rules out further a possibility of 
A1752 acting as an entry inhibitor of HIV-1.
Time‑of‑addition (TOA) assay: the antiviral effect of A1752 
occurs in the late phase of HIV‑1 replication
To further verify the point at which A1752 specifically 
acts in the viral life cycle, we also performed a TOA assay 
as described previously [37]. Following infection, the 
MT-4 cells were treated at various time points with the 
indicated control HIV-1 inhibitors. The inhibitors used 
for the analysis were AZT, Tenofovir, and Raltegravir, 
representing the HIV-1 life cycle early phase inhibitors, 
while SAMT and Lopinavir were the late phase inhibi-
tors. The viral supernatants were collected, and viral pro-
duction was analyzed for 24 h after the infection (Fig. 5). 
While viruses were produced continuously over the 24 h 
period in the DMSO control, virus production was sup-
pressed within 2  h by treatment of AZT and Tenofovir, 
6  h by Raltegravir, and 14  h by SAMT and Lopinavir, 
respectively. This was expected and showed the reliabil-
ity of the experimental condition as previously reported 
[37]. Under these conditions, the A1752 suppressed the 
viral production at around 14 h similar to Lopinavir and 
SAMT, which confirmed further that A1752 functions as 
a late-phase inhibitor of HIV-1. This also correlated well 
with the target point of its antiviral activity where the NC 
is known to function most importantly, mediating the 
production of infectious viruses.
A1752 inhibits the proper processing of Gag proteins
It has been shown by many genetic studies that one of the 
phenotypes generated by mutations in NC is the failure 
of viral particles to attain full maturation due to the inhi-
bition of proper gRNA dimerization and Gag polyprotein 
processing [38]. This eventually results in a loss of viral 
infectivity. It was also reported previously that NC inhib-
itors like DIBA and SAMT at high concentrations gen-
erated unprocessed Gag proteins, which accumulated in 
virion [20, 39]. Therefore, we investigated the effects of 
A1752 on the processing of Gag proteins in virion. Inter-
estingly, a protein band of about 30 kD was distinctively 
and specifically detected with A1752 treatment (Fig. 6a). 
Moreover, the level of unprocessed Gag increased nota-
bly, Capsid (CA) was slightly shifted, and molecules 
higher than 75  kD were also accumulated in the virion 
dose-dependently (Fig.  6a). Particularly, we estimated 
that the 30 kD protein band might be the size of CA-NC 
and might have been produced by the incomplete cleav-
age between CA and NC during the processing of the 
Gag protein. To clarify this observation, we analyzed the 
virion proteins in a parallel comparison with bacterial cell 
lysates expressing the CA-NC fusion protein and identi-
fied the 30 kD protein band as a form of CA-NC, which 
was indeed probed equally with NC and CA antibodies 
(Fig.  6b, c). In addition, the CA band slightly shifted in 
Fig.  6a was appeared to be an unprocessed form of CA 
and SP1. To demonstrate this further, we also analysed 
the virion generated with A1752 treatment in compari-
son with bacterial cell lysates expressing a CASP1 fusion 
protein (Fig.  6d), confirming further that the shifted 
band is undoubtedly the CASP1 form. These suggest that 
the generation of the abnormal protein might be due to 
interference in the processing of the junctions between 
Fig. 5 Time of addition assay. The MT‑4 cell were treated with the 
indicated inhibitors every 2 h for up to 24 h after virus infection and 
then virus production was determined at the indicated times using 
HIV‑1 p24 ELISA as described in “Methods”
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Fig. 6 A1752 generates aberrant Gag protein processing. The virus particles produced from MT‑4 cells in the presence of A1752 (a, d), and from 
293FT cells transfected with HIV‑1 proviral plasmid and treated with the indicated inhibitors (b–c) were analyzed using western blot assay. The 
membranes were probed with either anti‑Gag (a, d), −NC (b) or −CA (c, d) antibodies as indicated, respectively. A CA‑NC and CASP1 form (25 KD) 
of Gag protein expressed in E. coli were used as a control. Double asterisk indicates a specific major protein band (30 kD) generated by A1752
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CA and NC caused by the binding of A1752 to NC in the 
Gag protein.
A1752 defers uncoating of HIV‑1 core in infected cells
The precise processing of the Gag protein is required for 
proper formation of HIV-1 cores, which is essential for 
a productive RT reaction for viral infectivity [40]. There-
fore, we investigated whether the inhibition of the Gag 
processing by A1752 could also induce an immature or 
abnormal HIV-1 core, which would inhibit the reverse 
transcription as observed in Fig. 3d. To examine this pos-
sibility, we analyzed the stability of the HIV-1 virion core 
produced in the presence of A1752 as reported previ-
ously [41]. It has been reported that the immature core 
is hyper-stable compared to the normal core and results 
in a slower uncoating rate [42], which has also been 
associated with the impaired replication phenotype. To 
examine the core integrity, we first obtained viruses from 
293FT cells transfected with the HIV-1-proviral DNA 
and also treated with A1752. An equivalent amount of 
the viruses were permeabilized with Melittin or Triton 
X-100 and then incubated at 37  °C for core disassembly 
and centrifuged at 28,500×g for 1 h 30 min. The result-
ing pellet and the supernatant fraction were analyzed 
using a western blot to probe the CA in the HIV-1 core 
and free CA protein, respectively. Exposure of the viri-
ons to increasing concentrations of Melittin (10–20  μg/
mL), or Triton X-100 (0.005–0.01 %), released the HIV-1 
CA and RT proteins from the disassembled core, thereby 
causing them to appear more in the supernatant fraction 
compared to the simultaneously analyzed pellet frac-
tion (Fig. 7 and Additional file 6: Figure S5). In contrast 
to the DMSO and Tenofovir control, treatment with 
A1752 caused the CA and RT proteins to be retained 
considerably more in the pellet fraction compared to 
the supernatant fraction under the same permeabiliza-
tion conditions. This indicates that the cores of the virion 
modified by the A1752 are hyper-stable compared to the 
others. These data suggest that the A1752 also affects the 
stability of the HIV-1 core as induced by the abnormal or 
immature core resulting from the improper Gag process-
ing. Collectively, the results suggests that the novel phe-
notype of the noninfectious virus production generated 
by A1752 would most likely be attributable all to the spe-
cific interaction of A1752 with NC, which inhibited the 
NC chaperone function and led to the abnormal process-
ing of the Gag protein in the virion generated.
Discussion
The HIV/acquired immune deficiency syndrome (AIDS) 
pandemic remains a global health problem. The anti-HIV 
drugs currently developed have been effective in control-
ling the progression of severe infection. However, the 
emergence of drug-resistant strains requires the urgent 
identification of new types of inhibitors with mechanisms 
of inhibition that differ from the existing drugs [43, 44]. 
The HIV-1 NC has been suggested to be a prime target 
for the development of new types of anti-HIV/AIDS 
inhibitors. NC is an essential protein required in many 
steps of viral replication and mutations in NC causes var-
ious abnormalities in the viruses, thereby decreasing its 
infectivity.
In this study, we identified a new NC-inhibitor, A1752, 
which showed good antiviral efficacy, and binds directly 
to HIV-1 NC with a strong affinity in the nM range of Kd 
(Fig.  2a). In addition, it effectively inhibited the nucleic 
chaperone functions of NC. The NC is required for the 
recognition of the Psi sequence in the viral gRNA, which 
is followed by dimerization and packaging of gRNA dur-
ing viral assembly [45]. Our results showed that A1752 
specifically and dose-dependently inhibited the NC-
induced Psi RNA dimerization by interfering with the spe-
cific interaction between the Psi RNA and NC (Fig. 2c). In 
addition, we observed that A1752 inhibited the NC-medi-
ated destabilization of cTAR DNA hairpin doubly-labeled 
at ends with a fluorophore/quencher pair (Fig. 2d). More-
over, treatment with A1752 produced viral particles that 
Fig. 7 A1752 induces abnormal HIV‑1 core stability. a, b The virus 
particles produced from HIV‑1 proviral plasmid‑transfected 293FT 
cells were treated with A1752 and permeabilized either by Melittin (a) 
or Triton X‑100 (b) at room temperature for 10 min and then exposed 
to a 37 °C for 30 min to disassemble the HIV‑1 core structure. The 
resulting viruses were fractionated to a pellet and supernatant by 
centrifugation as described in “Methods”, and subjected to western 
blot analysis with anti‑CA (a) or anti‑RT (b) antibodies
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completely lost their infectivity (Figs. 3c, 4). Furthermore, 
this effect was far more efficient than some NC zinc fin-
ger inhibitors, which were previously reported to induce 
the loss of viral infectivity but required much higher doses 
than ours [20]. In addition, we also observed that the 
A1752 disrupted the proper processing of Gag. Specifi-
cally, the cleavage of the CA and NC precursor (CA-NC) 
was disrupted (Fig. 6). These results strongly suggest that 
one of the underlining mechanisms of the generation of 
the non-infectious phenotype by A1752 might be associ-
ated with the improper Gag processing of viral protease. 
This improper processing may be as a result of the modifi-
cation of the NC domain induced by the binding of A1752 
during viral maturation. Previously, it was also shown that 
some of the known zinc ejector NC inhibitors induced 
the modification of NC and cross-linking of Gag protein 
[20, 39]. For example, SAMT inhibits the Gag processing 
although this effect was observed at a rather high concen-
tration of 100 μM and was barely detected at the level of 
its IC50 (Fig. 6). In contrast, A1752 is much more efficient 
in this phenomenon, indicating that it is a highly effective 
inhibitor of NC.
HIV-1 maturation, particularly normal formation and 
processing of the viral core, is very critical for optimal 
viral infectivity [46]. The generation of an immature/
aberrant HIV-1 core is a phenotype that is frequently 
observed with NC mutants [9–11] and more recent evi-
dence strongly suggest that the proper uncoating of the 
virus is an essential step at the early stage of infection of 
target cells [47]. The A1752 appears to have induced an 
increase in the unprocessed CA-NC precursor as seen in 
Fig. 6, which might have caused incomplete viral matura-
tion resulting in a deficiency in the functionality of the 
HIV-1 core formation [48]. Therefore, we further exam-
ined the viral core abnormality induced by the A1752 and 
found indeed that it was much more refractory compared 
with the wild types in releasing the RT proteins in core 
(Fig. 7). This would have led to the failure of the reverse 
transcription as shown by our detection of the significant 
suppression of the synthesis of early RT products (-ss)
DNA (Fig.  3d). Therefore, it could be deduced that the 
modification of the core stability induced by the A1752 
might also have inhibited the normal uncoating process 
in the modified viral infected cells. Furthermore, based 
on the inhibition of the NC-mediated cTAR destabi-
lization by the A1752 (Fig.  2d), a similar inhibition of 
the chaperone activities of the NC by the A1752 could 
also have contributed to defects in the RT process post 
infection.
Conclusions
In summary, we have identified A1752, a new type of NC 
inhibitor, which specifically binds to the relevant target 
and exhibits good antiviral activity. The A1752 strongly 
binds to NC and thereby interferes with the chaperone 
functions of NC as well as the Gag processing. Conse-
quently, this action produces non-infectious and abnor-
mal viruses that are defective in uncoating and viral 
reverse transcription in cells following infection. There-
fore, these results suggest that these unique properties of 
A1752 support the proposition that it is a functional NC 
inhibitor and could serve as an excellent novel candidate 
molecule for the development of a new anti-HIV drug.
Methods
Infection, transfection, and reinfection
The MT4 and 293FT cells were maintained in RPMI and 
DMEM, respectively, and the media contained 10 % FBS 
(Hyclone, Logan, UT), penicillin, and streptomycin sul-
fate (GIBCO, Carlsbad, CA). The MT4 cells were infected 
with the NL4-3 isolate-derived HIV-1, which had the 
nef gene replaced with EGFP and were treated simul-
taneously with the inhibitors as indicated. The 293FT 
cells were typically transfected with 1  μg the NL43/
EGFP-proviral DNA using lipofectamine2000 (Invit-
rogen, Carlsbad, CA). Following a 6-h transfection, the 
media were changed and cells were treated with the test 
compounds. Post infection day 3 or post transfection 
36  h, the viral supernatants were collected for further 
analysis and the remaining cells were analyzed for GFP 
expression. For the reinfection assay, the viral superna-
tant produced in the presence of the compounds was 
first centrifuged at 900×g for 10 min, filtered through a 
0.45-μm filter to remove the cell debris. The viruses were 
then further purified and concentrated by centrifugation 
at 28,500×g for 3 h to remove any remaining inhibitors 
used in infection assay. The resulting pellet was resus-
pended in serum-free fresh RPMI to yield virus stocks. 
An equivalent amount (typically 2.5  ng) of virion was 
used to re-infect fresh MT4 cells. Post infection at 48 h, 
the expression of GFP was examined followed by a FACS 
analysis for quantification.
HIV‑1 p24 ELISA assay
The amounts of virus particles of each sample were deter-
mined using an HIV-1 p24 ELISA kit as recommended 
by the manufacturer’s instruction (Advanced Bioscience 
Laboratories, Rockville, MD), which uses monoclonal 
antibodies against p24 epitopes for the detection of p24 
antigen.
Lentivirus preparation and HT108 cell colony assay
The pLenti/EGFP transgene vector and packaging plas-
mids pLP1, pLP2, and pLP/VSVG plasmids encoding 
the viral proteins Gag-Pol, Rev, and VSV-G, respectively, 
were prepared and used for transfection as described 
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previously [49]. The infectivity of the lentivirus generated 
with and without the inhibitors was determined using a 
colony assay following the manufacturer’s instructions 
(Invitrogen, Carlsbad, CA). Briefly, 1 × 105 HT1080 cells 
were first placed in a 35 mm dish. On the following day, 
the lentiviral supernatants were serially diluted tenfold 
five times in a total volume of 1  ml, and added to each 
well to attain a 6 μg/mL final concentration of polybrene 
(Sigma, St. Louis, MO). After incubation at 37  °C over-
night, the media were replaced with 2  mL of DMEM. 
After a day, the media were changed again to fresh 
DMEM containing blasticidin (5 μg/mL final concentra-
tion, Sigma) and the cells were incubated further at 37 °C 
for 14  days with media changes performed every other 
day. After 14  days of selection, each well was washed 
twice with 1 mL PBS and incubated with 1 mL of crys-
tal violet solution (1  % crystal violet, Sigma, 10  % etha-
nol) for 10 min at room temperature. Then the cells were 
washed with 1 mL PBS four times to remove the excess 
crystal violet, and the stained colonies were counted for 
viral titer determination.
Cell cytotoxicity assay
The cytotoxicity was measured using an ATP-based assay. 
For the determination of the CC50 of the compounds, 
MT4 cells (1 × 104 cells) were seeded in a white 96-well 
plate in 100  µL volume with compounds (0–50  μM). 
After 5 days, the plate was treated with 25 μL of CellTi-
ter-Glo reagent (Promega, Fitchburg, WI) per well, mixed 
for 2 min on shaker to induce cell lysis, and then further 
incubated at room temperature for 10 min and subjected 
to luminescence recording on a spectraMax lumines-
cence microplate reader (Molecular Device) according to 
the manufacturer’s instructions.
SPR and tryptophan fluorescence quenching assay
For the SPR assay, the NC protein (GenScript, Piscata-
way, NJ) was immobilized to a CM5 chip contained in a 
10 mM sodium acetate buffer (pH 5.5) solution. The test 
compounds were diluted in 5  % DMSO and allowed to 
flow on chip in PBS running buffer at the rate of 30 μL 
per min for 120  s. The affinity was measured using a 
Biacore T100 instrument and the data evaluation was 
processed to acquire all the binding strength and kinetic 
parameters with the analysis program provided by the 
manufacturer (GE Healthcare, USA) [50, 51]. The trypto-
phan quenching of NC (5 μM) was performed in a buffer 
containing 10 mM sodium phosphate and 10 % glycerol 
with or without A1752. The decrease in fluorescence was 
measured at excitation and emission wavelengths of 280 
and 340 nm, respectively, using a spectraMax Gemini Em 
fluorescence microplate reader (Molecular Device).
Psi RNA dimerization and gel shift assay
The pcDNA/psi/EGFP plasmid which contain a T7 pro-
moter directly upstream of the HIV-1 Psi sequence (895–
1019) [52] was linearized by a BamHI as a template for 
the transcription. The Psi RNA molecules were prepared 
in  vitro using the RiboMAX™ large scale RNA produc-
tion systems SP6 and T7 (Promega, Fitchburg, WI) fol-
lowing the manufacturer’s protocol. A total of 5  μM of 
NC was incubated with A1752 or AZT at an increasing 
molar ratio of A1752 (1:1, 1:10, 1:25, and 1:50) or AZT 
(1:50) to NC at room temperature for 30 min. Then, 2 μM 
of Psi RNA was denatured for 10 min at 105 °C and then 
chilled on ice for 5  min. The denatured RNA was then 
incubated with the NC-compound mixture in the follow-
ing order, 10 μL of NC (5 μM)-compound mixture, 4 μL 
of 5 × NC buffer containing 100 mM Tris–Cl (pH 7.5), 
250 mM NaCl, 25 mM dithiothreitol, 1 mM MgCl2, and 
6 μL of denatured RNA (3 μM). The mixtures were incu-
bated for 30 min at room temperature. At the end of the 
incubation, the mixtures were loaded on a pre-run 8  % 
non-denaturing polyacrylamide gel and electrophoresed 
at 100 V for 40 min in TBE buffer. After electrophoresis, 
the RNA was visualized by staining with SYBR® Green I 
nucleic acid gel-stain solution (Molecular Probes. Carls-
bad, CA) The RNA-binding protein was visualized by 
staining with SYPRO® Ruby EMSA protein gel-stain 
solution (Molecular Probes. Carlsbad, CA).
cTAR DNA destabilization
The doubly-labeled cTAR DNA oligonucleotides (55 nts) 
were synthesized at a 0.2 μmol scale and purified by the 
manufacturer (Bioneer Inc., Daejeon, Korea). The labe-
ling dyes were Rh6G and DABCYL at the 5′ and 3′ ends 
of the cTAR DNA, respectively. All experiments were 
performed at room temperature in 25  mM Tris–HCl 
(pH 7.5), 30 mM NaCl, and 0.2 mM MgCl2, and the NC 
was incubated with labeled cTAR DNA at a molar ratio 
of 10:1. The fluorescence was recorded on a spectraMax 
fluorescence microplate reader (Molecular Device) and 
the excitation and emission wavelengths were 520 and 
560 nm, respectively.
Analysis of viral DNA in infected cells
The MT4 cells (1 ×  105) were with infected HIV-1 cor-
responding to 20 ng of HIV-1 p24, unless specified oth-
erwise, and then harvested after 6  h. The total cellular 
DNA was extracted using the DNeasy blood and tissue 
kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instruction and analyzed by qPCR using the 
following HIV-1- specific oligonucleotides, Forward 
(5′-CAAGTAGTGTGTGCCCGTCTGTT-3′), Reverse 
(5′-CTG CTAGAGATTTTTCCACACTGAC-3′).
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Viral RNA analysis
The total RNA after viral infection was extracted with 
Trizol reagent (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s instructions. The viral RNA was ana-
lyzed using a northern blot assay. A total of 3 μg of RNA 
was denatured at 68 °C in sample buffer containing 6.5 % 
formaldehyde, 50 % formamide, 1X MOPS, 5 % glycerol, 
and 0.04 % bromophenol blue for 15 min and separated 
on a 0.8  % agarose gel containing 2.2  M formaldehyde. 
This was then transferred to nylon membrane (Roche, 
Indianapolis, IN). After transfer, the RNA was fixed to 
the membrane by UV cross-linking. For hybridization, a 
digoxigenin (DIG)-labeled riboprobe system was used. 
The riboprobes which corresponded to the Gag (790–
1285 nt) sequences of pNL43GFP were synthesized by 
in vitro transcription using T7 polymerase according to 
the instruction of the Dig Northern Starter Kit (Roche, 
Indianapolis, IN), and the actin probe provided in the 
kit was used. The hybridization and detection were per-
formed according to the manufacturer’s instructions.
HIV‑1 Core uncoating assay
An equivalent amount of viruses were pemeabilized with 
the reagents such as Melittin (Sigma) or Triton X-100 and 
then exposed to heat for 30 min to disassemble the HIV-1 
core structure as described previously [41]. The resulting 
viruses were centrifuged for 1 h 30 min at 28,500×g. The 
resulting pellet and supernatant fractions were analyzed 
using western blot.
Western blot analysis
An equivalent amount virion was heat-denatured in the 
sample buffer containing 8  % SDS, 250  mM Tris–HCl 
(pH 6.8), 40  % glycerol, 0.02  % bromophenol blue, and 
5 % β-mercaptoethanol (95 °C) for 10 min and then ana-
lyzed by SDS-PAGE (12  %). After transfer the proteins 
to the membrane it was probed with anti-p55 (1:10,000, 
Thermo Scientific, Pittsburgh, PA), anti-p24 (1:10,000, 
Abcam, Cambridge, MA), anti-NC (1:5000, a gift from 
Dr. Robert J. Gorelick at the NCI-Frederick Cancer 
Research), and anti-RT antibodies (1:10,000, Abcam, 
Cambridge, MA).
Time of addition (TOA) assay
The TOA assay was performed as described previously 
[37]. Briefly, MT4 cells were infected with the NL43-
derived HIV-1 bearing GFP (0.5 MOI) and treated with 
the test compounds at concentrations corresponding to 
10–100 fold of the IC50 of each compound at predeter-
mined times. Post infection (24 h), the cells were analyzed 
to detect the GFP content and the viral supernatants for 
the virus production were titrated using a p24 ELISA.
HIV‑1 reverse transcriptase assay
The RT assays were performed using a non-radioac-
tive fluorometric method [53]. The poly(A) substrates, 
oligo(dT) primers and PicoGreen fluorophore were pro-
vided by the EnzChek reverse transcriptase assay kit (Inv-
itrogen, Carlsbad, CA). After hybridization, the primers 
were elongated to long RNA-DNA heteroduplexes in the 
presence of the RT (3 units, Abcam) with or without the 
test compounds, and the formation of the heteroduplexes 
was correlated with the RT activity. Finally, the Pico-
Green fluorophore incorporating into the RNA-DNA 
duplexes was added, and the activity of the RT was meas-
ured using a fluorometer. The concentration of the test 
compound was 0.3–100 μM.
HIV‑1 integrase assay
The integrase assays were colorimetrically performed 
using a HIV-1 integrase assay kit (XpressBio Co, Thur-
mont, MD) according to the manufacturer’s instructions 
[54]. The concentration of the test compounds was 0.1–
100 μM, and the percentage of the integrase activity was 
calculated by dividing the mean value of the test com-
pound with that of the DMSO control.
Additional files
Additional file 1: Figure S1. Effect of the A1752 on reverse transcriptase 
activity in vitro. The percentage inhibition of in vitro RT activity by the 
compounds indicated at different concentrations is shown. Nevirapine 
and Etravirine, both HIV‑1 non‑nucleoside reverse transcriptase inhibitors, 
were used as positive controls. Data are the mean ± SEM of three separate 
experiments.
Additional file 2: Figure S2. In vitro assay of A1752′s effect on HIV‑1 
integrase activity. In vitro integrase assays were performed with the com‑
pounds indicated at concentrations ranging from 0.1–100 μM. Raltegravir 
and Elvitegravir were used as positive controls. Data are the mean ± SEM 
of three separate experiments.
Additional file 3: Table S1. Analysis of binding kinetics and affinity 
between NCp7 and A1752.
Additional file 4: Figure S3. Determination of NC‑mediated cTAR DNA 
destabilization. Emission spectra of Rh6G‑5′‑cTAR‑3′‑DABCYL (0.1 μM) 
were measured in the absence or in the presence of NC (1 μM). Excitation 
wavelength was fixed at 520 nm and emission wavelength was scanned 
at 450 to 650 nm. One representative of two independent experiments 
was shown.
Additional file 5: Figure S4. Inhibition of HIV‑1 gRNA packaging in a 
high concentration of A1752. MT4 cells were infected with treatment 
of the inhibitors indicated. The viral genomic RNA was isolated from 
concentrated viral supernatant followed by northern blot analysis using 
Gag‑specific probes.
Additional file 6: Figure S5. Induction of hyper‑stable core of HIV‑1 
by A1752. MT4 cells were infected with HIV‑1 NL4‑3/EGFP virus together 
with the A1752 and Tenofovir treatment at an increasing concentration. 
The released virus particles were permeabilized with melittin at indicated 
amounts, followed by incubation at 37 °C for 30 min. The pellet and 
supernatant fraction were analyzed using western blot assays with anti‑CA 
antibodies.
Page 14 of 15Kim et al. Retrovirology  (2015) 12:90 
Authors’ contributions
MK, SHK, JAP, SIJ, and JCY conceived the experiments; MK, SHK, JAP, KLY, BSK, 
ESL performed the experiments and analyzed data; MK and JCY wrote the 
manuscript. All authors contributed to the assembly of the figures. All authors 
read and approved the final manuscript.
Author details
1 Avixgen Inc., Seoul 137‑701, Korea. 2 National Research Laboratory of Molec‑
ular Virology, Department of Pathology, School of Medicine, The Catholic 
University of Korea, Seoul 137‑701, Korea. 
Acknowledgements
We thank Gyoonhee Han and R. J. Gorelick for providing chemicals and 
reagents. We are also grateful to the members of J. C. Y laboratory for technical 
assistance and critical readings on the manuscript. This work was supported 
by a Grant of the Korea Healthcare technology R&D Project, Ministry of Health 
and Welfare (A121925) and in part by a research grant from the National 
Research Foundation of Korea (2008‑2004183 and 2013R1A2A2A01068353).
Competing interests
All authors declare that they have no competing interests.
Received: 26 February 2015   Accepted: 22 October 2015
References
 1. Bell NM, Lever AM. HIV Gag polyprotein: processing and early viral parti‑
cle assembly. Trend Microbiol. 2013;21(3):136–44.
 2. Darlix JL, Godet J, Ivanyi‑Nagy R, Fosse P, Mauffret O, Mely Y. Flexible 
nature and specific functions of the HIV‑1 nucleocapsid protein. J Mol 
Biol. 2011;410(4):565–81.
 3. Freed EO. HIV‑1 gag proteins: diverse functions in the virus life cycle. Virol‑
ogy. 1998;251(1):1–15.
 4. Rein A, Henderson LE, Levin JG. Nucleic‑acid‑chaperone activity of 
retroviral nucleocapsid proteins: significance for viral replication. Trend 
Biochem Sci. 1998;23(8):297–301.
 5. Meric C, Goff SP. Characterization of Moloney murine leukemia virus 
mutants with single‑amino‑acid substitutions in the Cys‑His box of the 
nucleocapsid protein. J Virol. 1989;63(4):1558–68.
 6. Gorelick RJ, Nigida SM Jr, Bess JW Jr, Arthur LO, Henderson LE, Rein A. 
Noninfectious human immunodeficiency virus type 1 mutants deficient 
in genomic RNA. J Virol. 1990;64(7):3207–11.
 7. Aldovini A, Young RA. Mutations of RNA and protein sequences involved 
in human immunodeficiency virus type 1 packaging result in production 
of noninfectious virus. J Virol. 1990;64(5):1920–6.
 8. Schmalzbauer E, Strack B, Dannull J, Guehmann S, Moelling K. Mutations 
of basic amino acids of NCp7 of human immunodeficiency virus type 1 
affect RNA binding in vitro. J Virol. 1996;70(2):771–7.
 9. Tanchou V, Decimo D, Pechoux C, Lener D, Rogemond V, Berthoux L, 
Ottmann M, Darlix JL. Role of the N‑terminal zinc finger of human immu‑
nodeficiency virus type 1 nucleocapsid protein in virus structure and 
replication. J Virol. 1998;72(5):4442–7.
 10. Ottmann M, Gabus C, Darlix JL. The central globular domain of the 
nucleocapsid protein of human immunodeficiency virus type 1 is critical 
for virion structure and infectivity. J Virol. 1995;69(3):1778–84.
 11. Berthoux L, Pechoux C, Ottmann M, Morel G, Darlix JL. Mutations in the 
N‑terminal domain of human immunodeficiency virus type 1 nucleocap‑
sid protein affect virion core structure and proviral DNA synthesis. J Virol. 
1997;71(9):6973–81.
 12. Musah RA. The HIV‑1 nucleocapsid zinc finger protein as a target of 
antiretroviral therapy. Curr Top Med Chem. 2004;4(15):1605–22.
 13. de Rocquigny H, Shvadchak V, Avilov S, Dong CZ, Dietrich U, Darlix JL, 
Mely Y. Targeting the viral nucleocapsid protein in anti‑HIV‑1 therapy. Mini 
Rev Med Chem. 2008;8(1):24–35.
 14. Rice WG, Schaeffer CA, Harten B, Villinger F, South TL, Summers MF, 
Henderson LE, Bess JW Jr, Arthur LO, McDougal JS, et al. Inhibition of 
HIV‑1 infectivity by zinc‑ejecting aromatic C‑nitroso compounds. Nature. 
1993;361(6411):473–5.
 15. Rice WG, Supko JG, Malspeis L, Buckheit RW Jr, Clanton D, Bu M, Graham 
L, Schaeffer CA, Turpin JA, Domagala J, et al. Inhibitors of HIV nucleocap‑
sid protein zinc fingers as candidates for the treatment of AIDS. Science. 
1995;270(5239):1194–7.
 16. Rice WG, Baker DC, Schaeffer CA, Graham L, Bu M, Terpening S, Clanton 
D, Schultz R, Bader JP, Buckheit RW Jr, et al. Inhibition of multiple phases 
of human immunodeficiency virus type 1 replication by a dithiane com‑
pound that attacks the conserved zinc fingers of retroviral nucleocapsid 
proteins. Antimicrob Agent Chemother. 1997;41(2):419–26.
 17. Rice WG, Turpin JA, Huang M, Clanton D, Buckheit RW Jr, Covell DG, 
Wallqvist A, McDonnell NB, DeGuzman RN, Summers MF, et al. Azodi‑
carbonamide inhibits HIV‑1 replication by targeting the nucleocapsid 
protein. Nat Med. 1997;3(3):341–5.
 18. Turpin JA, Song Y, Inman JK, Huang M, Wallqvist A, Maynard A, Covell 
DG, Rice WG, Appella E. Synthesis and biological properties of novel 
pyridinioalkanoyl thiolesters (PATE) as anti‑HIV‑1 agents that target the 
viral nucleocapsid protein zinc fingers. J Med Chem. 1999;42(1):67–86.
 19. Goel A, Mazur SJ, Fattah RJ, Hartman TL, Turpin JA, Huang M, Rice WG, 
Appella E, Inman JK. Benzamide‑based thiolcarbamates: a new class of 
HIV‑1 NCp7 inhibitors. Bioorg Med Chem Lett. 2002;12(5):767–70.
 20. Jenkins LMM, Ott DE, Hayashi R, Coren LV, Wang D, Xu Q, Schito ML, 
Inman JK, Appella DH, Appella E. Small‑molecule inactivation of 
HIV‑1 NCp7 by repetitive intracellular acyl transfer. Nat Chem Biol. 
2010;6(12):887–9.
 21. Turpin JA, Schito ML, Jenkins LM, Inman JK, Appella E. Topical micro‑
bicides: a promising approach for controlling the AIDS pandemic via 
retroviral zinc finger inhibitors. Adv Pharmacol. 2008;56:229–56.
 22. Jenkins LM, Durell SR, Maynard AT, Stahl SJ, Inman JK, Appella E, Legault P, 
Omichinski JG. Comparison of the specificity of interaction of cellular and 
viral zinc‑binding domains with 2‑mercaptobenzamide thioesters. J Am 
Chem Soc. 2006;128(36):11964–76.
 23. Pannecouque C, Szafarowicz B, Volkova N, Bakulev V, Dehaen W, Mely Y, 
Daelemans D. Inhibition of HIV‑1 replication by a bis‑thiadiazolbenzene‑
1,2‑diamine that chelates zinc ions from retroviral nucleocapsid zinc 
fingers. Antimicrob Agents Chemother. 2010;54(4):1461–8.
 24. Vercruysse T, Basta B, Dehaen W, Humbert N, Balzarini J, Debaene F, 
Sanglier‑Cianferani S, Pannecouque C, Mely Y, Daelemans D. A phenyl‑
thiadiazolylidene‑amine derivative ejects zinc from retroviral nucleocap‑
sid zinc fingers and inactivates HIV virions. Retrovirology. 2012;9:95.
 25. Lapadat‑Tapolsky M, De Rocquigny H, Van Gent D, Roques B, Plasterk R, 
Darlix JL. Interactions between HIV‑1 nucleocapsid protein and viral DNA 
may have important functions in the viral life cycle. Nucleic Acid Res. 
1993;21(4):831–9.
 26. Feng YX, Copeland TD, Henderson LE, Gorelick RJ, Bosche WJ, Levin JG, 
Rein A. HIV‑1 nucleocapsid protein induces “maturation” of dimeric retro‑
viral RNA in vitro. Proc Natl Acad Sci USA. 1996;93(15):7577–81.
 27. Levin JG, Guo J, Rouzina I, Musier‑Forsyth K. Nucleic acid chaperone activ‑
ity of HIV‑1 nucleocapsid protein: critical role in reverse transcription and 
molecular mechanism. Prog Nucleic Acid Res Mol Biol. 2005;80:217–86.
 28. Vo MN, Barany G, Rouzina I, Musier‑Forsyth K. Mechanistic studies of 
mini‑TAR RNA/DNA annealing in the absence and presence of HIV‑1 
nucleocapsid protein. J Mol Biol. 2006;363(1):244–61.
 29. Shvadchak V, Sanglier S, Rocle S, Villa P, Haiech J, Hibert M, Van Dorsselaer 
A, Mely Y, de Rocquigny H. Identification by high throughput screening 
of small compounds inhibiting the nucleic acid destabilization activity of 
the HIV‑1 nucleocapsid protein. Biochimie. 2009;91(7):916–23.
 30. Cruceanu M, Stephen AG, Beuning PJ, Gorelick RJ, Fisher RJ, Williams MC. 
Single DNA molecule stretching measures the activity of chemicals that 
target the HIV‑1 nucleocapsid protein. Anal Biochem. 2006;358(2):159–70.
 31. Stephen AG, Worthy KM, Towler E, Mikovits JA, Sei S, Roberts P, Yang QE, 
Akee RK, Klausmeyer P, McCloud TG, et al. Identification of HIV‑1 nucle‑
ocapsid protein: nucleic acid antagonists with cellular anti‑HIV activity. 
Biochem Biophys Res Commun. 2002;296(5):1228–37.
 32. Breuer S, Chang MW, Yuan J, Torbett BE. Identification of HIV‑1 inhibitors 
targeting the nucleocapsid protein. J Med Chem. 2012;55(11):4968–77.
 33. Jang SI, Kim YH, Paik SY, You JC. Development of a cell‑based assay prob‑
ing the specific interaction between the human immunodeficiency virus 
type 1 nucleocapsid and psi RNA in vivo. J Virol. 2007;81(11):6151–5.
 34. Lee AH, Han JM, Sung YC. Generation of the replication‑competent 
human immunodeficiency virus type 1 which expresses a jellyfish green 
fluorescent protein. Biochem Biophys Res Commun. 1997;233(1):288–92.
Page 15 of 15Kim et al. Retrovirology  (2015) 12:90 
 35. Godet J, Boudier C, Humbert N, Ivanyi‑Nagy R, Darlix JL, Mely Y. Compara‑
tive nucleic acid chaperone properties of the nucleocapsid protein NCp7 
and Tat protein of HIV‑1. Virus Res. 2012;169(2):349–60.
 36. Beltz H, Clauss C, Piemont E, Ficheux D, Gorelick RJ, Roques B, Gabus 
C, Darlix JL, de Rocquigny H, Mely Y. Structural determinants of HIV‑1 
nucleocapsid protein for cTAR DNA binding and destabilization, and 
correlation with inhibition of self‑primed DNA synthesis. J Mol Biol. 
2005;348(5):1113–26.
 37. Daelemans D, Pauwels R, De Clercq E, Pannecouque C. A time‑of‑drug 
addition approach to target identification of antiviral compounds. Nat 
Protoc. 2011;6(6):925–33.
 38. Grigorov B, Decimo D, Smagulova F, Pechoux C, Mougel M, Muriaux D, 
Darlix JL. Intracellular HIV‑1 Gag localization is impaired by mutations in 
the nucleocapsid zinc fingers. Retrovirology. 2007;4:54.
 39. Turpin JA, Terpening SJ, Schaeffer CA, Yu G, Glover CJ, Felsted RL, Sausville 
EA, Rice WG. Inhibitors of human immunodeficiency virus type 1 zinc 
fingers prevent normal processing of gag precursors and result in the 
release of noninfectious virus particles. J Virol. 1996;70(9):6180–9.
 40. Kawamura M, Shimano R, Inubushi R, Amano K, Ogasawara T, Akari H, 
Adachi A. Cleavage of Gag precursor is required for early replication 
phase of HIV‑1. FEBS Lett. 1997;415(2):227–30.
 41. Ohagen A, Gabuzda D. Role of Vif in stability of the human immunodefi‑
ciency virus type 1 core. J Virol. 2000;74(23):11055–66.
 42. Muller B, Anders M, Reinstein J. In vitro analysis of human immunodefi‑
ciency virus particle dissociation: gag proteolytic processing influences 
dissociation kinetics. PLoS One. 2014;9(6):e99504.
 43. Peters BS, Conway K. Therapy for HIV: past, present, and future. Adv Dent 
Res. 2011;23(1):23–7.
 44. Kumari G, Singh RK. Anti‑HIV drug development: structural features and 
limitations of present day drugs and future challenges in the successful 
HIV/AIDS treatment. Curr Pharm Des. 2013;19(10):1767–83.
 45. Lever AM. HIV‑1 RNA packaging. Adv Pharmacol. 2007;55:1–32.
 46. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a 
human immunodeficiency virus type 1 core of optimal stability is crucial 
for viral replication. J Virol. 2002;76(11):5667–77.
 47. Kono K, Takeda E, Tsutsui H, Kuroishi A, Hulme AE, Hope TJ, Nakayama 
EE, Shioda T. Slower uncoating is associated with impaired replicative 
capability of simian‑tropic HIV‑1. PLoS One. 2013;8(8):e72531.
 48. Muller B, Anders M, Akiyama H, Welsch S, Glass B, Nikovics K, Clavel F, 
Tervo HM, Keppler OT, Krausslich HG. HIV‑1 Gag processing intermedi‑
ates trans‑dominantly interfere with HIV‑1 infectivity. J Biol Chem. 
2009;284(43):29692–703.
 49. Kim SH, Jun HJ, Jang SI, You JC. The determination of importance of 
sequences neighboring the Psi sequence in lentiviral vector transduction 
and packaging efficiency. PLoS One. 2012;7(11):e50148.
 50. Biacore TM Assay Handbook 29‑0194‑00 Edition AA. GE Healthcare Life 
Sciences. 2012.
 51. Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, 
Wilson IA, Sanders RW, Moore JP, et al. Differential binding of neutralizing 
and non‑neutralizing antibodies to native‑like soluble HIV‑1 Env trimers, 
uncleaved Env proteins, and monomeric subunits. Retrovirology. 2014;11:41.
 52. Ka WH, Jeong YY, You JC. Identification of the HIV‑1 packaging RNA 
sequence (Psi) as a major determinant for the translation inhibi‑
tion conferred by the HIV‑1 5′ UTR. Biochem Biophys Res Commun. 
2012;417(1):501–7.
 53. Paskaleva EE, Lin X, Duus K, McSharry JJ, Veille JC, Thornber C, Liu Y, Lee 
DY, Canki M. Sargassum fusiforme fraction is a potent and specific inhibi‑
tor of HIV‑1 fusion and reverse transcriptase. Virol J. 2008;5:8.
 54. Chen L, Ao Z, Jayappa KD, Kobinger G, Liu S, Wu G, Wainberg MA, 
Yao X. Characterization of antiviral activity of benzamide deriva‑
tive AH0109 against HIV‑1 infection. Antimicrob Agent Chemother. 
2013;57(8):3547–54.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
